Cargando…
Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials
BACKGROUND: Response rate (RR), the most common early means of assessing oncology drugs, is not suitable as the sole endpoint for phase II trials of drugs which induce disease stability but not regression. Time to progression (TTP) may be more sensitive to such agents, but induces recruitment delays...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3259049/ https://www.ncbi.nlm.nih.gov/pubmed/22151297 http://dx.doi.org/10.1186/1471-2288-11-164 |